MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on developing and commercializing products that fulfill unmet medical needs. MiddleBrook currently markets KEFLEX, the immediate-release brand of cephalexin, and MOXATAG – the first and only FDA-approved once-daily amoxicillin.

We have developed a proprietary delivery technology called PULSYS, which enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. MOXATAG is our first product utilizing our proprietary PULSYS technology. While MiddleBrook is currently focused on the anti-infective arena, we see opportunities for PULSYS products in the anti-fungal, antiviral, and oncology markets as well.

Jan 5, 2010
MiddleBrook Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 4350
+ more info
Dec 3, 2009
MiddleBrook Pharmaceuticals Reduces Field Sales Force and Corporate Staff, Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement
+ more info
Nov 5, 2009
MiddleBrook Pharmaceuticals Reports Third Quarter 2009 Results
+ more info